Is quetiapine a drug of abuse? Reexamining the issue of addiction

Expert Opinion on Drug Safety

Volumn 7, Issue 6, 2008, Pages 739-748

  Tcheremissine, Oleg V ^a  

^a LEVINE CANCER INSTITUTE   (United States)

Author keywords

Abuse; Addiction; Benzodiazepines; Quetiapine; Substance abuse disorder; SUD

Indexed keywords

ACETYLSALICYLIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BROMAZEPAM; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLONIDINE; DIPHENHYDRAMINE; HALOPERIDOL; LORAZEPAM; QUETIAPINE; SEDATIVE AGENT; THIORIDAZINE; TRAZODONE; VITAMIN;

BEDTIME DOSAGE; BIPOLAR DISORDER; BORDERLINE STATE; DRUG DEPENDENCE; DRUG DETOXIFICATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MISUSE; DRUG SELF ADMINISTRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENERALIZED ANXIETY DISORDER; HUMAN; MEDLINE; OPIATE ADDICTION; PATIENT COMPLIANCE; PERSONALITY DISORDER; PRISONER; PSYCHOSIS; PSYCINFO; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ADDICTIVE; DIBENZOTHIAZEPINES; DRUG AND NARCOTIC CONTROL; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 57049162654     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330802496883     Document Type: Review

References (93)

1. World Health Organization. Neuroscience of psychoactive substance use and dependence. WHO: Geneva; 2004
2. Uhl GR, Grow RW. The burden of complex genetics in brain disorders. Arch Gen Psychiatry 2004;61:223-9
3. Kuehn BM. Prescription drug abuse rises globally. JAMA 2007;297(12):1306
4. McCarthy M. Prescription drug abuse up sharply in the USA. Lancet 2007;369(9572):1505-6
5. Hertz JA, Knight JR. Prescription drug misuse: a growing national problem. Adolesc Med Clin 2006;17:751-69
6. Substance Abuse and Mental Health Services Administration. Results from the 2004 National Survey on Drug use and Health: National Findings. NSDUH Series H-30, DHHS Publication N0 SMA 05-4194: Rockville, MD; 2005
7. Available from: http://www.inshealth.com/media [Last accessed 1 June 2008]
8. Mintzes B, Bare ML, Kravitz RL, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA? CMAJ 2003;169(5):405-12
9. Griffiths RR, Johnson MW. Relative abuse liability of hypnotics drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005;66(suppl 9):31-41
10. Zacny J, Bigelow G, Compton P, et al. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 2003;69:215-32
11. Compton WM, Volkow ND. Abuse of prescription drugs and risks of addiction. Drug Alcohol Depend 2004;83(suppl):S4-7
12. Wuncsh MJ, Nakamoto K, Goswami A, Schnoll SH. Prescription drug abuse among prisoners in rural Southwestern Virginia. J Addict Dis 2007;26(4):15-22
13. Vartzopoulos D, Krull F. Dependence on monoamine oxidase inhibitors in high dose. Br J Psychiatry 1991;158:856-7
14. Lichtigfeld FJ, Gillman MA. The possible abuse of and dependence on major tranquillizers and tricyclic antidepressants. S Afr Med J 1994;84:5
15. Haddad P. Do antidepressants have any potential to cause addiction? J Psychopharmacology 1999;13(3):300-7
16. Nutt DJ. Death and dependence: current controversies over the selective serotonin reuptake inhibitors. J Psychopharmacology 2003;17(4):355-64
17. Pierre JM, Shnayder I, Wirshing DA, Wirshing WC. Intranasal quetiapine abuse. Am J Psychiatry 2004;161(9):1718
18. Hussain MZ, Waheed W, Hussain S. Intravenous quetiapine abuse. Am J Psychiatry 2005;162(9):1755-6
19. Morin AK. Possible intranasal quetiapine misuse. Am J Health Syst Pharm 2007;64:723-5
20. Waters BM, Joshi KG. Intravenous quetiapine-cocaine use ("Q-Ball"). Am J Psychiatry 2007;164(1):173-4
21. Pinta ER, Taylor RE. Quetiapine addiction? Am J Psychiatry 2007;164(1):174-5
22. Reeves RR, Brister JC. Additional evidence of the abuse potential of quetiapine. South Med J 2007;100(8):834-6
23. Paparrigopoulos T, Karaiskos D, Liappas J. Quetiapine: Another drug with potential for misuse? A case report. J Clin Psychiatry 2008;69(1):162-3
24. Murphy D, Bailey K, Stone M, Wirshing WC. Addictive potential of quetiapine. Am J Psychiatry 2008;165(7):918
25. Keltner NL, Vance DE. Incarcerated care and quetiapine abuse. Perspect Psychiatr Care 2008;44(3):202-6
26. Borison RL, Arvanitis LA, Miller BG. ICI 204, 636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996;16(2):158-69
27. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66(1):111-21
28. Vieta E, Calabrese JR, Goikolea JM, et al. BOLDER Study Group. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007;9(4):413-25
29. Saller CF, Salarm AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993;112(2-3):285-92
30. Hyman S. Addiction: a disease of learning and memory. Am J Psychiatry 2005;162:1414-22
31. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002;159:1642-52
32. Roberts DC, Koob GF, Klonoff P, et al. Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of nucleus accumbens. Pharmacol Biochem Behav 1980;12:781-7
33. Volkow ND, Fowler JS, Wang GJ. Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 2002;13:355-66
34. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci 2005;8:1445-9
35. Nestler EJ. From neurobiology to treatment: progress against addiction. Nat Neurosci 2002;5(suppl):1076-9
36. Wise RA. Brain reward circuitry: insights from unsensed incentives. Neuron 2002;36:229-40
37. Schultz W. Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol 1997;7:191-7
38. Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron 1998;21:467-76
39. Nestler EJ. Molecular basis of neural plasticity underlying addiction. Nat Rev Neurosci 2001;2:119-28
40. Nestler EJ. Under siege: the brain on opiates. Neuron 1996;16:897-900
41. O'Brien CP. Research advances in the understanding and treatment of addiction. Am J Addict 2003;12(suppl 2):36-47
42. DuPont RL. Biology and the environment-rethinking demand reduction. J Addict Dis 1999;18(4):121-38
43. De Wit H, Griffiths RR. Testing the abuse liability of anxiolytics and hypnotic drugs in humans. Drug Alcohol Depend 1991;28:83-111
44. Brady KT, Myrick H, McElroy SL. The relationship between substance use disorders, impulse control disorders, and pathological aggression. Am J Addict 1998;7:221-30
45. Tcheremissine OV, Lane SD, Cherek DR, et al. Impulsiveness and other personality dimensions in substance use disorders and conduct disorder. Addict Disord Their Treat 2003;2:1-7
46. Koob GF. Drug addiction: the yin and the yang of hedonic homeostasis. Neuron 1996;16:893-6
47. Moeller FG, Dougherty DM, Barratt ES, et al. The impact of impulsivity on cocaine use and retention in treatment. J Subst Abuse Treat 2001;21(4):193-8
48. Davidson M, Baum WM. Choice of variable environment: Every reinforcer counts. JEAB 2000;74:1-24
49. Goldberg SR, Spealman RD, Kelleher RT. Enhancement of drug-seeking behavior by environmental stimuli associated with cocaine or morphine injections. Neuropharmacology 1979;18:1015-7
50. Childress AR, Mozley PD, McElgin W, et al. Limbic activation during cue-induced cocaine craving. Am J Psychiatry 1999;156;11-8
51. Lau CE, Neal SA, Falk JL. Schedule-induced polydipsic choice between cocaine and lidocaine solutions: critical importance of associative history. Behav Pharmacol 1996;7(8):731-41
52. Caggiula AR, Donny EC, White AR, et al. Cue dependency of nicotine self-administration and smoking. Pharmacol Biochem Behav 2001;70:515-30
53. Balster RL, Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 2003;70(suppl 3):13-40
54. Chen L, Tsong Y. Design and analysis for drug abuse potential studies: issues and strategies fro implementing a crossover design. DIAJ 2007;41:481-9
55. Schoedel KA, Sellers EM. Assessing abuse liability during drug development: changing standards and expectations. Nature 2008;83(4):622-6
56. Cami J, Bigelow GE, Griffiths RR, Drummond DC. Special issue: clinical testing of drug abuse liability. Br J Addict 1991;86:1525-652
57. Ator NA, Griffiths RR. Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 2003;70(suppl3):S55-72
58. Griffiths RR, Bigelow GE, Ator NA. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend 2003;70(suppl 3):S41-54
59. Goldstein RZ, Alia-Klein N, Tomasi D, et al. Is decreased prefrontal cortical sensitivity to monetary reward associated with impaired motivation and self-control in cocaine addiction? Am J Psychiatry 2007;164(1):43-51
60. Roache JD, Griffiths RR. Comparison of triazolam and pentobarbital: performance impairment, subjective effects and abuse liability. J Pharmacol Exp Ther 1985;248:120-33
61. Roache JD, Griffiths RR. Repeated administration of diazepam and triazolam to subjects with histories of drug abuse. Drug Alcohol Depend 1986;17:15-29
62. Griffiths RR, McLeod DR, Bigelow GE, et al. Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects. Psychopharmacology (Berl) 1984;84:147-54
63. Roache JD, Griffiths RR. Lorazepam and meprobamate dose effects in humans: behavioral effects and abuse liability. J Pharmacol Exp Ther 1987;243:978-88
64. Evans SM, Funderburk FR, Griffiths RR. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 1990;255:1246-55
65. Tarasoff G, Osti K. Black-market value of antipsychotics, antidepressants, and hypnotics in Las Vegas, Nevada. Am J Psychiatry 2007;164(2):350
66. Griffiths RR, Weerts EM. Benzodiazepine self-adminiscration in humans and laboratory animals-implications for problems of long-term use and abuse. Psychopharmacology (Berl) 1997;134:1-37
67. Troisi JR, Critchfield TS, Griffiths RR. Buspirone and lorazepam abuse liability in humans: behavioral effects, subjective effects and choice. Behav Pharmacol 1993;4:217-30
68. Evans SM, Griffiths RR, De Wit H. preference for diazepam, but not buspirone, in moderate drinkers. Psychopharmacology (Berl) 1996;123:154-63
69. Jaffe J, Bloor R, Crome I, et al. A postmarketing study of relative abuse liability of hypnotic drugs. Addiction 2004;99:165-73
70. Joyce M, Khan A, Atkins S, et al. Efficacy and safety of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder (GAD). Poster presented at the 161 st Annual Meeting of the American Psychiatric Association; 3-8 May 2008; Washington: DC, USA
71. Katzman M, Brawman-Mintzer O, Reyes E, et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy in maintenance treatment of generalized anxiety disorder (GAD): efficacy and tolerability results from a randomized, placebo-controlled trial. Poster presented at the 161st Annual Meeting of the American Psychiatric Association; 3-8 May 2008; Washington: DC, USA
72. Abreu ME, Bigelow GE, Fleisher L, Walsh SL. Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology (Berl) 2001;154:76-84
73. Roset PN, Farre M, Dela Torre R, et al. Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males. Drug Alcohol Depend 2001;64:285-98
74. De Wit, Dudish S, Amber J. Subjective and behavioral effects of diazepam depend on its rate of onset. Psychopharmacology (Berl) 1993;112:324-30
75. Griffiths RR, Wolf B. Relative abuse potential of different benzodiazepines in drug abusers. J Clin Psychopharmacol 1990;10:237-43
76. Mumford GK, Evans SM, Fleishaker JC, Griffiths RR. Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Ther 1995;57:356-65
77. Sigmon SC. Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement. Exp Clin Psychopharmacol 2007;15(1):1-20
78. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001;40(7):509-22
79. Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release versus immediate-release formulation: a position emission tomography study. J Clin Psychiatry 2008;69(1):81-6
80. Dews PB. Studies on behavior. I. Differential sensitivity to pentobarbital of pecking performance in pigeons depending on the schedule of reward. J Pharmacol Exp Ther 1955;138:393-401
81. Green TA, Gehrke BJ, Bardo MT. Environmental enrichment decreases intravenous amphetamine self-administration in rats: dose-response functions for fixed- and progressive-ratio schedules. Psychopharmacology (Berl) 2002;162(4):373-8
82. Brown ES, Nejtek VA, Perantie DC, Bobadilla L. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord 2002;4:406-11
83. Martinotti G, Andreoli S, Di Nicola M, et al. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol 2008;23(5):417-24
84. Monnelly P, Ciraulo DA, Knapp C, et al. Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol 2004;24:532-5
85. Longoria J, Brown ES, Perantie DC, et al. Quetiapine for alcohol abuse use and craving in bipolar disorder. J Clin Psychopharmacol 2004;24(1):101-2
86. Weisman RL. Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report. Int J Psychiatry Med 2003;33(1):85-9
87. Cohen MJ, Hanbury R, Stiminet B. Abuse of amitriptyline. JAMA 1978;240:1372
88. Price JS, Waller PC, Wood SM, et al. A comparison of the postmarketing safety of four selective serotonin reuptake inhibitors including the investigation of symptoms occurring o withdrawal. Br J Clin Pharmacol 1996;42:757-63
89. Macvicar K. Abuse of antiparkinsonian drugs by psychiatric patients. Am J Psychiatry 1977;134(7):809-11
90. Land W, Pinsky D, Salzman C. Abuse and misuse of anticholinergic medications. Hosp Commun Psychiatry 1991;42:580-1
91. Dilsaver S. Antimuscarinic agents as substance of abuse: review. J Clin Psychopharmacol 1988;8:14-22
92. Reeves RR. Abuse of olanzapine by substance abusers. J Psychoactive Drugs 2007;39(3):297-9
93. Gardos G, Cole JO, Tarsy D. Withdrawal syndrome associated with antipsychotics. Am J Psychiatry 1978;135:1321-4